It targets healthcare providers and patients affected by heart failure, neuromuscular, and rare muscle diseases, with a focus on the U.S. and global biopharmaceutical markets.How does the transaction value relate to Cytokinetics, Incorporated's one-year stock performance? The ~$323,650 sale occurred with shares priced at $64.73, following a 27.36% total return for the stock over the preceding 12 months as of the transaction date.What is the current value of the insider's remaining direct position? Based on ...